Cargando…

Human Pluripotent Stem Cell-Derived Cardiomyocytes for Assessment of Anticancer Drug-Induced Cardiotoxicity

Cardiotoxicity is a major cause of high attrition rates among newly developed drugs. Moreover, anti-cancer treatment-induced cardiotoxicity is one of the leading reasons of mortality in cancer survivors. Cardiotoxicity screening in vitro may improve predictivity of cardiotoxicity by novel drugs, usi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schwach, Verena, Slaats, Rolf H., Passier, Robert
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Cardiovascular Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7156610/ https://www.ncbi.nlm.nih.gov/pubmed/32322588 http://dx.doi.org/10.3389/fcvm.2020.00050

Ejemplares similares

Automated image analysis system for studying cardiotoxicity in human pluripotent stem cell-Derived cardiomyocytes
por: Cao, Lu, et al.
Publicado: (2020)

Using human induced pluripotent stem cell-derived cardiomyocytes to understand the mechanisms driving cardiomyocyte maturation
por: Hamledari, Homa, et al.
Publicado: (2022)

Transplantation of Human Pluripotent Stem Cell-Derived Cardiomyocytes for Cardiac Regenerative Therapy
por: Silver, Sophia E., et al.
Publicado: (2021)

Cardiotoxicity of Anticancer Therapeutics
por: Dong, Jerry, et al.
Publicado: (2018)

Cardiotoxicity of Anticancer Drugs: Molecular Mechanisms and Strategies for Cardioprotection
por: Morelli, Marco Bruno, et al.
Publicado: (2022)

Cardiotoxicity and Heart Failure: Lessons from Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes and Anticancer Drugs
por: Sachinidis, Agapios
Publicado: (2020)

Challenges and innovation: Disease modeling using human-induced pluripotent stem cell-derived cardiomyocytes
por: Reilly, Louise, et al.
Publicado: (2022)

Development of a Contractile Cardiac Fiber From Pluripotent Stem Cell Derived Cardiomyocytes
por: Hansen, Katrina J., et al.
Publicado: (2018)

Trends and Limitations in the Assessment of the Contractile Properties of Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes From Patients With Dilated Cardiomyopathy
por: Ito, Masamichi, et al.
Publicado: (2020)

Case report: Transplantation of human induced pluripotent stem cell-derived cardiomyocyte patches for ischemic cardiomyopathy
por: Miyagawa, Shigeru, et al.
Publicado: (2022)

Cardiomyocyte Atrophy, an Underestimated Contributor in Doxorubicin-Induced Cardiotoxicity
por: Chen, De-Shu, et al.
Publicado: (2022)

microRNA-377 Signaling Modulates Anticancer Drug-Induced Cardiotoxicity in Mice
por: Henderson, John, et al.
Publicado: (2021)

Measuring Both pH and O(2) with a Single On-Chip Sensor in Cultures of Human Pluripotent Stem Cell-Derived Cardiomyocytes to Track Induced Changes in Cellular Metabolism
por: Tanumihardja, Esther, et al.
Publicado: (2020)

In vivo tracking transplanted cardiomyocytes derived from human induced pluripotent stem cells using nuclear medicine imaging
por: Saito, Yukihiro, et al.
Publicado: (2023)

Alteration of N(6)-Methyladenosine mRNA Methylation in a Human Stem Cell-Derived Cardiomyocyte Model of Tyrosine Kinase Inhibitor-Induced Cardiotoxicity
por: Ma, Yan, et al.
Publicado: (2022)

Targeting GPCRs Against Cardiotoxicity Induced by Anticancer Treatments
por: Audebrand, Anais, et al.
Publicado: (2020)

Deciphering Common Long QT Syndrome Using CRISPR/Cas9 in Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes
por: Song, Yongfei, et al.
Publicado: (2022)

Improved Atrial Differentiation of Human Pluripotent Stem Cells by Activation of Retinoic Acid Receptor Alpha (RARα)
por: Schwach, Verena, et al.
Publicado: (2022)

New Insights in Early Detection of Anticancer Drug-Related Cardiotoxicity Using Perfusion and Metabolic Imaging
por: Cadour, Farah, et al.
Publicado: (2022)

Regulation of Ion Channel Function in Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes by Cancer Cell Secretion Through DNA Methylation
por: Zhong, Rujia, et al.
Publicado: (2022)

Modeling Doxorubicin-Induced Cardiotoxicity in Human Pluripotent Stem Cell Derived-Cardiomyocytes
por: Maillet, Agnes, et al.
Publicado: (2016)

Safety confirmation of induced pluripotent stem cell-derived cardiomyocyte patch transplantation for ischemic cardiomyopathy: first three case reports
por: Kawamura, Takuji, et al.
Publicado: (2023)

Atrial-like cardiomyocytes from human pluripotent stem cells are a robust preclinical model for assessing atrial-selective pharmacology
por: Devalla, Harsha D, et al.
Publicado: (2015)

Co-transplantation of Mesenchymal Stromal Cells and Induced Pluripotent Stem Cell-Derived Cardiomyocytes Improves Cardiac Function After Myocardial Damage
por: Neef, Klaus, et al.
Publicado: (2022)

Functional cardiotoxicity assessment of cosmetic compounds using human-induced pluripotent stem cell-derived cardiomyocytes
por: Chaudhari, Umesh, et al.
Publicado: (2017)

Modelling cadmium‐induced cardiotoxicity using human pluripotent stem cell‐derived cardiomyocytes
por: Shen, Jiaxi, et al.
Publicado: (2018)

Cardiotoxicity of Antineoplastic Therapies and Applications of Induced Pluripotent Stem Cell-Derived Cardiomyocytes
por: Huang, Mo-Fan, et al.
Publicado: (2021)

Deep learning detects cardiotoxicity in a high-content screen with induced pluripotent stem cell-derived cardiomyocytes
por: Grafton, Francis, et al.
Publicado: (2021)

Cardiotoxicity evaluation using human embryonic stem cells and induced pluripotent stem cell-derived cardiomyocytes
por: Zhao, Qi, et al.
Publicado: (2017)

Liensinine- and Neferine-Induced Cardiotoxicity in Primary Neonatal Rat Cardiomyocytes and Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes
por: Yu, Yangyang, et al.
Publicado: (2016)

Epicardial injection of allogeneic human-induced-pluripotent stem cell-derived cardiomyocytes in patients with advanced heart failure: protocol for a phase I/IIa dose-escalation clinical trial
por: Zhang, He, et al.
Publicado: (2022)

Cardiac MRI assessment of anthracycline-induced cardiotoxicity
por: Mabudian, Leila, et al.
Publicado: (2022)

Pharmacogenomics in drug-induced cardiotoxicity: Current status and the future
por: Li, Mo-Yun, et al.
Publicado: (2022)

Evaluation of the Cardiotoxicity of Mitragynine and Its Analogues Using Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes
por: Lu, Jun, et al.
Publicado: (2014)

Conventional rigid 2D substrates cause complex contractile signals in monolayers of human induced pluripotent stem cell‐derived cardiomyocytes
por: Huethorst, Eline, et al.
Publicado: (2021)

Human Pluripotent Stem Cells for Modeling of Anticancer Therapy-Induced Cardiotoxicity and Cardioprotective Drug Discovery
por: Keung, Wendy, et al.
Publicado: (2021)

Cardiotoxicity of Anthracyclines
por: Cardinale, Daniela, et al.
Publicado: (2020)

Cardiotoxicity of anti-cancer drugs: cellular mechanisms and clinical implications
por: Kwok, Cecilia, et al.
Publicado: (2023)

Maturation strategies and limitations of induced pluripotent stem cell-derived cardiomyocytes
por: Wu, Peng, et al.
Publicado: (2021)

Melphalan induces cardiotoxicity through oxidative stress in cardiomyocytes derived from human induced pluripotent stem cells
por: Liu, Rui, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_nok20mqqkceq2uo226smtjan5m